How to manage toxicities associated with bispecific antibody therapy for MM in community practice
The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the management of toxicities associated with bispecific antibody therapy for multiple myeloma (MM) in community practice.
In this interview, Mateos discusses practical considerations for the management of adverse events (AEs) associated with bispecific antibodies in MM. Mateos outlines how to recognize and manage cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), as well as strategies to mitigate infection risk. Mateos also discusses…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.